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ABSTRACT 
Acute myeloid leukemia (AML) results from the over-proliferation of progenitor cells of the 
myeloid lineage in the bone marrow. It is a heterogeneous disease that is aggressive and 
difficult to treat. AML diagnosis is based on clinical as well as laboratory investigations. Risk 
stratification is important to assess risk of relapse. Current guidelines for risk stratification are 
dependent on identification of genetic aberrations particularly chromosomal translocations 
and gene mutations. Though these are observed in the majority of patients, the best treatment 
regimen remains elusive. AML blasts are assumed to have transformed from a normal 
counterpart and maintains many normal regulatory functions. Early features such as stem cell 
properties has long been proven to be linked to early relapse in AML. Leukaemia stem cells 
(LSC) are identified by high CD34 and negative CD38 expression. Aberrant expression of a 
third marker such as Thy-1/CD90 negativity, expression of CLL-1 and IL-3R (CD123), 
intermediate levels of aldehyde dehydrogenase and co-expression of common chromosomal 
translocation may be used to distinguish from normal hematopoietic stem cells. In vitro 
characteristics of AML blasts such as proliferation, survival or response to treatment are also 
able to predict patient response to therapy, replicative of its interaction with the 
microenvironment. These potential prognostic markers are well studied but are currently not 
considered in patient management.  
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